Accepted sessions
| Author(s) | Session | Submission Date |
|---|---|---|
| Jacqueline A Hannam (1) |
Paracetamol and diclofenac additive effects after tonsillectomy Oral presentation Background: Paracetamol combined with diclofenac is commonly used to control postoperative pain in children. Diclofenac pharmacokinetics, and paracetamol pharmacokinetics (PK) and dynamics (PD) (analgesia) have been described with these drugs used separately (1, 2). A model for the combination of paracetamol with diclofenac would be useful for improving analgesia in children. |
1 February 2012 |
| Cornelia B Landersdorfer (1,2) |
Population Modelling of Vildagliptin as an Inhibitor and Substrate of Dipeptidylpeptidase IV and its Effects on Glucagon-Like Peptide 1, Glucose, and Insulin Oral presentation Background. Vildagliptin acts by inhibiting dipeptidyl peptidase IV (DPP-4), thereby increases active GLP-1 (glucagon-like peptide 1) concentrations and decreases plasma glucose in diabetic patients. Objectives. To develop a mechanism-based population PK/PD model that simultaneously describes and predicts vildagliptin pharmacokinetics and its effects on DPP-4 activity and the underlying glucose-... |
31 January 2012 |
| Julie Simpson |
Treatment of malaria: from drug discovery to optimisation of current therapies. Oral presentation |
31 January 2012 |
| Aaron Basing (1) |
The design of a pharmacokinetic study of Intranasal Fentanyl Oral presentation Objective: To create a sampling schedule for a population pharmacokinetic study of Intranasal Fentanyl (INF) in paediatric patients presenting to the emergency department of a tertiary care hospital. |
31 January 2012 |
| Jürgen B. Bulitta (1,3) |
Mechanism-based modelling of antibiotics to optimally cure patients and prevent resistance: progress, gaps, and future perspectives Oral presentation Background: Substantial progress of mechanism-based and empirical modelling for anti-infectives over the past decade has enabled these models to rationally translate the time-course of killing and emergence of resistance from in vitro to animal infection models and ultimately to patients. Objectives: To illustrate applications of translational mechanism-based models for anti-infective mono- and... |
31 January 2012 |
| Anita Sumpter (1,2) |
A model for maturation of milrinone clearance from prematurity to adulthood Oral presentation Objectives: Background: Methods: Results: Conclusions: References: |
30 January 2012 |
| Saião A (1,2), Febra C (3), Duarte A (3), Lobato R (2), Duffull S (4), Isbister GK (1) |
Assessment of vancomycin dosing regimens in Intensive Care Unit patients with impaired renal function Oral presentation Despite the large utilization of vancomycin in methicillin resistant Staphylococcus aureus (MRSA) infections, there is limited information regarding the proper dosing regimen in intensive care unit patients with impaired renal function. The objective of this study was (i) to conduct a population pharmacokinetic analysis of vancomycin in a population of critically ill patients; (ii) to assess the... |
30 January 2012 |
| Kashyap Patel (1) |
Mechanism-based population modelling of dihydoartemisinin pharmacodynamics in murine malaria Oral presentation Background: Murine models are powerful tools for studying erythrocytic stages of malaria infection, because parasite morphology and development are similar to that in human malaria. However, mechanism-based pharmacodynamic (PD) models for antimalarials are generally lacking, and are required to optimise dosing. Objectives: To describe the growth cycle for Plasmodium berghei and the parasitocidal... |
30 January 2012 |
| Kris M Jamsen (1) |
Optimal designs for pharmacokinetic-pharmacodynamic studies of dihydroartemisinin following oral artesunate Oral presentation Background: Artemisinin derivatives are the main drugs used for the treatment of uncomplicated malaria. Although these drugs remain the most powerful anti-parasitic agents available, there is now evidence for parasite resistance to artesunate, the most widely used artemisinin derivative [1]. This finding provides motivation for conducting more pharmacokinetic-pharmacodynamic (PK-PD)... |
30 January 2012 |
| Oskar Alskär (1,2) |
Development and application of a pharmacokinetic model for the glycation of albumin Oral presentation Background |
30 January 2012 |
| Sarapee Hirankarn (1) |
Pharmacokinetics of high-dose methotrexate in children with cancer: A mechanism-based evaluation of clearance prediction Oral presentation Background |
27 January 2012 |
| Stefanie Hennig (1,2) |
Which matrix is the most reliable to judge the inclusion of covariates: reduction of unexplained parameter variability, increase in explained parameter variability or change in OFV? Poster presentation Background: |
27 January 2012 |
| Areej Turkistani (1) |
A clinical trial incident: Why simple PK is sometimes not so simple Oral presentation The antibiotic dose calculator trial in children aims to find out if a web based dose calculator is better than department protocols used in 3 clinical units for achieving target concentrations of amikacin, gentamicin or vancomycin. |
26 January 2012 |
| Troels K Bergmann (1) |
Prediction correction: quick fix for VPC misdiagnosis in a tacrolimus popPK model Poster presentation After spending weeks on modelling with little progress it occurred to us that the problem might lie with the diagnostic – not the model. |
25 January 2012 |
| Nick Holford (1) |
What is the between cycle variability in methotrexate clearance? Oral presentation Background |
18 January 2012 |
| Sam Holford (1) |
NextDose - A web based collaborative tool for dose individualisation Oral presentation A web based collaborative tool has been developed for helping with dose individualisation. It has been applied to dosing busulphan for conditioning prior to marrow transplantation. |
18 January 2012 |
| Anita Sumpter (1) |
A model for fat free mass in humans from very premature neonates to young adults Oral presentation Objectives: To describe the maturation of fat free mass (FFM) from prematurity to adulthood as a function of postmenstrual age (PMA) using nonlinear mixed effect modeling. |
18 January 2012 |
| Katie Owens |
The pharmacokinetic profile of intravenous paracetamol in adult patients undergoing major abdominal surgery: A population analysis Oral presentation The aim of the present study was to determine the effect of major surgery on paracetamol glucuronidation and sulfation. 53 patients were given doses of either 1, 1.5 or 2 g of paracetamol by intravenous (IV) infusion. A combination of rich and sparse plasma and urine samples were collected over a 7 day period (Day 0 being preoperative collection and Days 1 to 6 being postoperative collection) for... |
17 January 2012 |
| Abhishek Gulati (1) |
Adaptive PD-optimal design of a pilot study for a clotting time test for enoxaparin Oral presentation Background: Dosing of enoxaparin, like other anticoagulants, may result in bleeding following excessive doses and clot formation if the dose is too low. There is no standard measure of enoxaparin clinical effectiveness. We recently showed that a Xa clotting time test could potentially assess the effect of enoxaparin on the clotting system [1]. Preliminary in vitro experiments using plasma from a... |
16 January 2012 |
| Hesham S Al-Sallami (1) |
Evaluation of a Bayesian dose-individualisation method for enoxaparin Oral presentation Background: |
16 January 2012 |
